0.000
Close （ET）Quotes delayed by 15 min
--Market Cap
--P/E TTM
undefined Earnings Date
Period
FY2024 Earnings Date
Revenue(YoY)
680.85M
46.62%
EPS(YoY)
-0.72
50.29%
Analyst Rating
2025-04-06
Financial Indicators
EPS
Revenue
Net Profit
Net Margin
Gross Margin
Debt to assets ratio
ROE
ROA
Relevant data have not been disclosed by the company yet.
Income Statement
Revenue
Operating profit
Net Profit
Relevant data have not been disclosed by the company yet.
Balance Sheet
Current assets
Total current liabilities
Total assets
Total liabilities
Total equity
Relevant data have not been disclosed by the company yet.
Cash Flow Statement
Net operating income
Net investment
Net financing
Relevant data have not been disclosed by the company yet.
FAQs
What is the total revenue of Intra-Cellular Therapies Inc?
According to Intra-Cellular Therapies Inc's FY2024 earnings report, its total revenue reached 680.85M, with a year-on-year change of 46.62%.
What is the Earnings Per Share (EPS) of Intra-Cellular Therapies Inc?
According to Intra-Cellular Therapies Inc's FY2024 earnings report, its Earnings Per Share (EPS) was -0.724, with a year-on-year change of 50.29%.
What is the net income of Intra-Cellular Therapies Inc?
According to Intra-Cellular Therapies Inc's FY2024 earnings report, its net income was -74.68M, with a year-on-year change of 46.54%.
What is the net margin of Intra-Cellular Therapies Inc?
According to Intra-Cellular Therapies Inc's FY2024 earnings report, its net profit margin was -10.97%, with a year-on-year change of 63.53%.
What is the gross margin of Intra-Cellular Therapies Inc?
According to Intra-Cellular Therapies Inc's FY2024 earnings report, its gross margin was 91.63%, with a year-on-year change of -1.19%.
What is the debt-to-asset ratio of Intra-Cellular Therapies Inc?
According to Intra-Cellular Therapies Inc's FY2024 earnings report, its debt-to-asset ratio was --, with a year-on-year change of --.
What is the Return on Equity (ROE) of Intra-Cellular Therapies Inc?
According to Intra-Cellular Therapies Inc's FY2024 earnings report, its Return on Equity (ROE) was -8.58%, with a year-on-year change of 61.67%.
What is the Return on Assets (ROA) of Intra-Cellular Therapies Inc?
According to Intra-Cellular Therapies Inc's FY2024 earnings report, its Return on Assets (ROA) was -7.13%, with a year-on-year change of 62.16%.
What is the operating profit of Intra-Cellular Therapies Inc?
According to Intra-Cellular Therapies Inc's FY2024 earnings report, its operating profit was -116.72M, with a year-on-year change of 26.77%.
What are the current assets of Intra-Cellular Therapies Inc?
According to Intra-Cellular Therapies Inc's FY2024 earnings report, its current assets were 1.31B, with a year-on-year change of 95.77%.
What are the total assets of Intra-Cellular Therapies Inc?
According to Intra-Cellular Therapies Inc's FY2024 earnings report, its total assets of Intra-Cellular Therapies Inc were 1.37B, with a year-on-year change of 87.69%.
What are the total liabilities of Intra-Cellular Therapies Inc?
According to Intra-Cellular Therapies Inc's FY2024 earnings report, its total liabilities of Intra-Cellular Therapies Inc were 218.45M, with a year-on-year change of 59.60%.
What is the total equity of Intra-Cellular Therapies Inc?
According to Intra-Cellular Therapies Inc's FY2024 earnings report, its total equity of Intra-Cellular Therapies Inc was 1.15B, with a year-on-year change of 94.19%.
What is the net operating income of Intra-Cellular Therapies Inc?
According to Intra-Cellular Therapies Inc's FY2024 earnings report, its net operating income of Intra-Cellular Therapies Inc was -74.68M, with a year-on-year change of 46.54%.
What is the net investment of Intra-Cellular Therapies Inc?
According to Intra-Cellular Therapies Inc's FY2024 earnings report, its net investment of Intra-Cellular Therapies Inc was -335.15M, with a year-on-year change of -417.55%.
What is the net financing of Intra-Cellular Therapies Inc?
According to Intra-Cellular Therapies Inc's FY2024 earnings report, its net financing of Intra-Cellular Therapies Inc was 567.51M, with a year-on-year change of 3086.46%.
